Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

PHASE4CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
SchizophreniaBipolar DisorderHealthyPsychosisSchizophreniform DisordersSchizo Affective DisorderMajor Depression With Psychotic Features
Interventions
OTHER

Placebo and fMRI

A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.

DRUG

Lorazepam and fMRI

A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Michigan

OTHER

NCT04004416 - Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis | Biotech Hunter | Biotech Hunter